Anti-inflammatory neuropeptides: A new class of endogenous immunoregulatory agents

Brain, Behavior, and Immunity

Volumn 22, Issue 8, 2008, Pages 1146-1151

  Delgado, Mario ^a   Ganea, Doina ^b  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antimicrobial peptides; Autoimmunity; Hormones; Inflammation; Neuropeptides; Regulatory T cells; Tolerance

Indexed keywords

ADRENOMEDULLIN; ANTIINFLAMMATORY AGENT; CORTISTATIN; GHRELIN; INTERMEDIN; NEUROPEPTIDE; UROCORTIN; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNITY; DOWN REGULATION; INNATE IMMUNITY; MELANOCYTE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AUTOIMMUNITY; HUMANS; IMMUNE TOLERANCE; INFLAMMATION; NEUROIMMUNOMODULATION; NEUROPEPTIDES; T-LYMPHOCYTES, REGULATORY;

EID: 52949150059     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbi.2008.06.001     Document Type: Article

References (51)

1. Allaker R.P., Grosvenor P.W., McAnerney D.C., Sheehan B.E., Srikanta B.H., Pell K., and Kapas S. Mechanisms of adrenomedullin antimicrobial action. Peptides 27 (2006) 661-666
2. Anton B., Leff P., Calva J.C., Acevedo R., Salazar A., Matus M., Pavon L., Martinez M., Meissier J.J., Adler M.W., Gaughan J.P., and Eisenstein T.K. Endomorphin 1 and endorphin 2 suppress in vitro antibody formation at ultra-low concentrations: anti-peptide antibodies but not ipoid antagonsists block the activity. Brain Behav.Immun. 22 (2008) 824-832
3. Bangale Y., Karle S., Planque S., Zhou Y.X., Taguchi H., Nishiyama Y., Li L., Kalaga R., and Paul S. VIPase autoantibodies in Fas-defective mice and patients with autoimmune disease. FASEB J. 17 (2003) 628-635
4. Blakeney J.S., and Fairlie D.P. Nonpeptide ligands that target peptide-activated GPCRs in inflammation. Curr. Med. Chem. 12 (2005) 3027-3042
5. Bluestone J.A. Regulatory T-cell therapy: is it ready for the clinic?. Nat. Rev. Immunol. 5 (2005) 343-349
6. Brogden K.A., Guthmiller J.M., Salzet M., and Zasloff M. The nervous system and innate immunity: the neuropeptide connection. Nat. Immunol. 6 (2005) 558-564
7. Colombo G., Sordi A., Lonati C., Carlin A., Turcatti F., Leonardi P., Gatti S., and Catania A. Treatment with α-melanocyte stimulating hormone preserves calciium regulatory proteins in rat heart allografts. Brain Behav. Immun. 22 (2008) 817-823
8. Chorny A., Anderson P., Gonzalez-Rey E., and Delgado M. Ghrelin protects against experimental sepsis by inhibiting high-mobility group box 1 release and by killing bacteria. J. Immunol. 180 (2008) 8369-8377
9. Chorny A., and Delgado M. Neuropeptides rescue mice from lethal sepsis by down-regulating the secretion of the late-acting inflammatory mediator high mobility group box 1. Am. J. Pathol. 172 (2008) 1297-1307
10. Chorny A., Gonzalez-Rey E., Varela N., Robledo G., and Delgado M. Signaling mechanisms of vasoactive intestinal peptide in inflammatory conditions. Regul. Pept. 137 (2006) 67-74
11. Cutuli M., Cristiani S., Lipton J.M., and Catania A. Antimicrobial effects of alpha-MSH peptides. J. Leukoc. Biol. 67 (2000) 233-239
12. Delgado M., Leceta J., and Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells. FASEB J. 16 (2002) 1844-1846
13. Delgado M., Pozo D., and Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol. Rev. 56 (2004) 249-290
14. Delgado, M., Varela, N., Gonzalez-Rey, E., 2008a. Vasoactive intestinal peptide protects against beta-amyloid-induced neurodegeneration by inhibiting microglia activation at multiple levels. Glia DOI:10.1002/glia.20681.
15. Delgado M., Toscano M.G., Benabdellah K., Cobo M., O'Valle F., Gonzalez-Rey E., and Marti{dotless}n F. In vivo delivery of lentiviral vectors expressing vasoactive intestinal peptide complementary DNA as gene therapy for collagen-induced arthritis. Arthritis Rheum. 58 (2008) 1026-1037
16. Delgado M., Robledo G., Rueda B., Varela N., ÓValle F., Hernandez-Cortes P., Caro M., Orozco G., Gonzalez-Rey E., and Martin J. Genetic association of vasoactive intestinal peptide with rheumatoid arthritis. Altered expression and signal in immune cells. Arthritis Rheum. 58 (2008) 1010-1019
17. Goetzl E.J., Voice J.K., Shen S., Dorsam G., Kong Y., West K.M., Morrison C.F., and Harmar A.J. Enhanced delayed-type hypersensitivity and diminished immediate type hypersensitivity in mice lacking the inducible VPAC(2) receptor for VIP. Proc. Natl. Acad. Sci. USA 98 (2001) 13854-13859
18. Gonzalez-Rey E., and Delgado M. Anti-inflammatory neuropeptide receptors: new therapeutic targets for immune disorders?. Trends Pharmacol. Sci. 28 (2007) 482-491
19. Gonzalez-Rey E., and Delgado M. Vasoactive intestinal peptide and regulatory T-cell induction: a new mechanism and therapeutic potential for immune homeostasis. Trends Mol. Med. 13 (2007) 241-251
20. Gonzalez-Rey E., Chorny A., and Delgado M. Therapeutic action of ghrelin in a mouse model of colitis. Gastroenterology 130 (2006) 1707-1720
21. Gonzalez-Rey E., Fernandez-Martin A., Chorny A., Martin J., Pozo D., Ganea D., and Delgado M. Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: downregulation of inflammatory and autoimmune responses. Am. J. Pathol. 168 (2006) 1179-1188
22. Gonzalez-Rey E., Chorny A., and Delgado M. Regulation of immune tolerance by anti-inflammatory neuropeptides. Nat. Rev. Immunol. 7 (2007) 52-63
23. Gonzalez-Rey E., Chorny A., Varela N., Del Moral R.G., and Delgado M. Therapeutic effect of cortistatin on experimental arthritis by downregulating inflammatory and Th1 responses. Ann. Rheum. Dis. 66 (2007) 582-588
24. Gonzalez-Rey E., and Delgado M. Vasoactive intestinal peptide inhibits cycloxygenase-2 expression in activated macrophages, microglia and dendritic cells. Brain Behav. Immun 22 (2008) 35-41
25. Goodnow C.C. Multistep pathogenesis of autoimmune diseases. Cell 130 (2002) 25-35
26. Gutierrez-Cañas I., Juarranz Y., Santiago B., Martinez C., Gomariz R.P., Pablos J.L., and Leceta J. Immunoregulatory properties of vasoactive intestinal peptide in human T cell subsets: implications for rheumatoid arthritis. Brain Behav. Immun. 22 (2008) 312-317
27. Juarranz Y., Gutierrez-Canas I., Santiago B., Carrion M., Pablos J.L., and Gomariz R.P. Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts. Arthritis Rheum. 58 (2008) 1086-1095
28. Lotze M.T., and Tracey K.J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 5 (2005) 331-342
29. Miksa M., Wu R., Cui W., Dong W., Das P., Simms H.H., Ravikuman T.S., and Wang P. Vasoactive hormone adrenomedullin and its binding protein: anti-inflammatory effects by up-regulating peroxisome proliferator-activating receptor-g. J. Immunol. 179 (2007) 6263-6272
30. Murthy R.G., Greco S.G., Taborga M., Patel N., and Rameshwar P. Tac1 regulation by RNA-binding protein and miRNA in bone marrow stroma: implication for hematopoietic activity. Brain Behav. Immun. 22 (2008) 442-450
31. Nathan C. Points of control in inflammation. Nature 420 (2002) 846-852
32. Nishida T., and Taylor A.W. Specific aqueous humor factors induce activation of regulatory T cells. Invest. Ophthalmol. Vis. Sci. 40 (1999) 2268-2274
33. Sharma V., Delgado M., and Ganea D. Granzyme B, a new player in activation-induced cell death, is down-regulated by vasoactive intestinal peptide in Th2 but not Th1 effectors. J. Immunol. 176 (2006) 97-110
34. Shibata M., Hisajima T., Nakano M., and Goris R.C. Funakoshi K. Morphological relationships between peptidergic nerve fibers and immunoglobulin A-producing lymphocytes in the mouse intestine. Brain Behav. Immun. 22 (2008) 158-166
35. Sternberg E.M. Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat. Rev. Immunol. 6 (2006) 318-328
36. Sun W., Hong J., Zang Y.C., Liu X., and Zhang J.Z. Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis. Int. Immunol. 18 (2006) 1691-1700
37. Szema A.M., Hamidi S.A., Lyubsky S., Dickman K.G., Mathew S., Abdel-Razek T., Chen J.J., Waschek J.A., and Said S.I. Mice lacking the VIP gene show airway hyperresponsiveness and airway inflammation, partially reversible by VIP. Am. J. Physiol. Lung Cell. Mol. Physiol. 291 (2006) 880-886
38. Taylor A., and Namba K. In vitro induction of CD25+ CD4+ regulatory T cells by the neuropeptide alpha-melanocyte stimulating hormone (alpha-MSH). Immunol. Cell. Biol. 79 (2001) 358-367
39. Taylor A.W., and Kitaichi N. The diminishment of experimental autoimmune encephalomyelitis (EAE) by neuropeptide alpha-melanocyte stimulating hormone (a-MSH) therapy. Brain Behav. Immun. 22 (2008) 634-646
40. Varela N., Chorny A., Gonzalez-Rey E., and Delgado M. Tuning inflammation with anti-inflammatory neuropeptides. Expert Opin. Biol. Ther. 7 (2007) 461-478
41. Voice J., Donnelly S., Dorsam G., Dolganov G., Paul S., and Goetzl E.J. Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice. J. Immunol. 170 (2003) 308-314
42. Voice J., Donnelly S., Dorsam G., Dolganov G., Paul S., and Goetzl E.J. c-Maf and JunB mediation of Th2 differentiation induced by the type 2 G protein-coupled receptor (VPAC2) for vasoactive intestinal peptide. J. Immunol. 172 (2004) 7289-7296
43. Vornhof-DeKrey E.E., Hermann R.J., Palmer M.F., Benton K., Dorsam S., and Dorsam G.P. TCR signalling and environment affect vasoactive intestinal peptide receptor-1 (VPAC-1) expression in primary mouse CD4 T cells. Brain Behav. Immun. 22 (2008) 1032-1040
44. Vornhof-DeKrey E.E., and Dorsam G.P. Stimulatory and suppressive signal transduction regulates vasoactive intestinal peptide receptor-1 (VPAC-1) in primary mouse CD4 T cells. Brain Behav. Immun. 22 (2008) 1024-1031
45. Wan Y.Y., and Flavell R.A. The roles for cytokines in the generation and maintenance of regulatory T cells. Immunol. Rev. 212 (2006) 114-130
46. Wang M.J., Lin S.Z., Kuo J.S., Hang H.Y., Tzeng S.F., Liao C.H., Chen D.C., and Chen W.F. Urocortin modulates inflammatory response and neurotoxicity induced by microglial activation. J. Immunol. 179 (2007) 6204-6214
47. Weckbecker G., Lewis I., Albert R., Schmid H.A., Hoyer D., and Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat. Rev. Drug Disc. 2 (2003) 999-1017
48. Yadav M., Rosenbaum J., and Goetzl E.J. Cutting Edge: Vasoactive intestinal peptide (VIP) induces differentiation of Th17 cells with a distinctive cytokine profile. J. Immunol. 180 (2008) 2772-2776
49. Yang H., Dixit V.D., Patel K., Vandanmagsar B., Collins G., Sun Y., Smith R.G., and Taub D.D. Reduction in hypophyseal growth hormone and prolactin expression due to deficiency in ghrelin receptor signalling is associated with Pit-1 suppression: relevance to the immune system. Brain Behav. Immun. 22 (2008) 1138-1145
50. Yoon S.W., Goh S.H., Chun J.S., Cho E.W., Lee M.K., Kim K.L., Kim J.J., Kim C.J., and Poo H. alpha-Melanocyte-stimulating hormone inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production in leukocytes by modulating protein kinase A, p38 kinase, and nuclear factor kappa B signaling pathways. J. Biol. Chem. 278 (2003) 32914-32920
51. Zafirova Y., Yordanov M., and Kalfin R. Antiarthritic effect of VIP in relation to the host resistance against Candida albicans infection. Int. Immunol. 6 (2004) 1125-1131